Is Roivant Sciences Ltd. (ROIV) Overvalued?
We dive into why Roivant Sciences Ltd. (ROIV) could be considered overvalued on 2026-11-10, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Michael Rose
Michael Rose
| Share Statistics | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $28,641.9 | $211.8 | 89% |
|
| Shares Out (Mil) | 722.8 | 55.4 | 91% |
|
| Institutional Ownership | 81.1% | 93.0% | 49% |
|
| Float (Mil) | 584.8 | 41.5 | 86% |
|
| Beta | 1.20 | 0.99 | 70% |
|
| Avg Daily Volume (000s) | 9,310 | 553 | 95% |
|
| Price Change (52-week) |
85.4% | 42.8% | 94% |
|
| Growth | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (19.0%) | 13.2% | 3% |
|
| Net Income (5yr) | 18.0% | (10.3%) | 70% |
|
| EPS (5yr) | 15.8% | 15.8% | 59 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (56.4%) | (15.7%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.410) | ($1.473) | ($1.613) | |
| Month Ago EPS | ($0.413) | ($1.580) | ($1.718) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.413) | ($1.580) | ($1.718) | |
| Year/Year Chg | 42.9% | 171.8% | (87.3%) | |
| Financials | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $41 | $41 | 18% |
|
| Net Income (TTM) (Mil) | ($344) | ($44) | 4% |
|
| EPS (TTM) | ($0.482) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($36) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $93 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $25,942 | $147 | 86% |
|
| Valuation | ROIV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.11 | 2.01 | 87% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | (838.2%) | (50.6%) | 0% |
|
| ROA | (6.9%) | (47.4%) | 27% |
|
| ROE | (8.2%) | (53.1%) | 28% |
|
| Liabilities to Assets | 7.6% | 29.7% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Roivant Sciences Ltd. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors